Pfizer Terminates Torcetrapib Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will investigate whether an increased risk of mortality is a class effect of CETP inhibitors.
You may also be interested in...
Pfizer Turns To Insider Ian Read To See It Into Post-Lipitor Era
The 32-year Pfizer veteran will take over for Jeffrey Kindler in a succession viewed as a surprise by Wall Street.
Pfizer Turns To Insider Ian Read To See It Into Post-Lipitor Era
The 32-year Pfizer veteran will take over for Jeffrey Kindler in a succession viewed as a surprise by Wall Street.
With Genentech Fully Integrated, Roche Lays Out Pipeline
In Roche's first research overview since acquiring Genentech last year, management sought to assure investors that the research engine that developed breakthrough blockbuster medicines like Herceptin and Avastin is still innovating